<DOC>
	<DOCNO>NCT01503515</DOCNO>
	<brief_summary>This randomized phase III trial study well caspofungin acetate work compare fluconazole voriconazole prevent fungal infection patient follow donor stem cell transplant . Caspofungin acetate , fluconazole , voriconazole may effective prevent fungal infection patient follow donor stem cell transplant . It yet know whether caspofungin acetate effective fluconazole voriconazole prevent fungal infection patient follow donor stem cell transplant .</brief_summary>
	<brief_title>Caspofungin Acetate , Fluconazole , Voriconazole Preventing Fungal Infections Patients Following Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine caspofungin ( caspofungin acetate ) associate low incidence proven/probable invasive fungal infection ( IFI ) first 42 day follow allogeneic hematopoietic cell transplantation ( HCT ) high-risk IFI compare azole ( fluconazole voriconazole ) prophylaxis . SECONDARY OBJECTIVES : I . To determine caspofungin associate low incidence proven/probable IFI first 100 day follow high-risk allogeneic HCT compare azole ( fluconazole voriconazole ) prophylaxis . ( Exploratory ) II . To determine caspofungin associate low incidence proven/probable IFI first 42 100 day follow high-risk allogeneic HCT compare fluconazole prophylaxis . ( Exploratory ) III . To determine caspofungin associate low incidence proven/probable IFI first 42 100 day follow high-risk allogeneic HCT compare voriconazole prophylaxis . ( Exploratory ) IV . To determine caspofungin associate superior fungal-free survival ( FFS ) ( time death proven/probable IFI ) 42 100 day follow high-risk allogeneic HCT compare azole prophylaxis . ( Exploratory ) V. To describe effect caspofungin azoles incidence severity acute graft-versus-host disease ( GVHD ) . ( Exploratory ) VI . To create deoxyribonucleic acid ( DNA ) specimen bank anticipation development biology correlative study explore relationship IFI single nucleotide polymorphism ( SNPs ) gene involve immunity . ( Exploratory ) OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive caspofungin acetate intravenously ( IV ) 1 hour daily ( QD ) begin within 24 hour allogeneic hematopoietic stem cell transplantation ( HSCT ) ( day -1 0 ) continue day 42 absence invasive fungal infection disease progression . ARM II : Patients receive fluconazole IV 1-2 hour QD orally ( PO ) QD ; voriconazole IV 1-2 hour QD PO twice daily ( BID ) begin within 24 hour allogeneic HSCT ( day -1 0 ) continue day 42 absence invasive fungal infection disease progression . After completion study treatment , patient follow day 100 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Age For center use fluconazole antifungal comparator : Age &gt; = 3 month &lt; 21 year For center use voriconazole antifungal comparator : Age &gt; = 2 year &lt; 21 year The patient must undergo allogeneic HCT donor ( include match relate ) stem cell source underlie condition Patients must performance status correspond Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 2 ; use Karnofsky patient &gt; 16 year age Lansky patient = &lt; 16 year age Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 OR serum creatinine base age/gender follow : 0.4 mg/dL ( 1 month &lt; 6 month age ) 0.5 mg/dL ( 6 month &lt; 1 year age ) 0.6 mg/dL ( 1 &lt; 2 year age ) 0.8 mg/dL ( 2 &lt; 6 year age ) 1.0 mg/dL ( 6 &lt; 10 year age ) 1.2 mg/dL ( 10 &lt; 13 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( &gt; = 16 year age ) Total bilirubin &lt; 2.5 mg/dL unless increase bilirubin attributable Gilbert 's syndrome Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 5 X upper limit normal ( ULN ) age All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Within 90 day enrollment : Patients prove probable invasive mold infection eligible Patients incompletely treat invasive yeast infection eligible Patients elevate galactomannan level ( &gt; = 0.5 index ) within 30 day prior time enrollment ( perform ) must full evaluation invasive aspergillosis ( include negative chest compute tomography [ CT ] scan ) time period eligible enrollment Patients receive treatment IFI eligible Patients history echinocandin azole hypersensitivity eligible Female patient childbearing potential eligible unless negative pregnancy test result obtain Sexually active patient reproductive potential eligible unless agree use effective contraceptive method duration study participation Lactating females eligible unless agree breastfeed infant</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>